drugset / Trial / NCT02610712

Clinical Trial of the Use of Ketamine in Treatment Resistant Depression

NCT02610712 ↗

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the efficacy of the use of intravenous low-dose ketamine in the treatment of treatment-resistant depression (TRD), as well as the changes in Glutamate neurotransmission and inflammatory serum markers.

Timeline

Start
2014-05
Primary completion
2017-12
Completion
—

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.5 mg/kg Intravenous